CIBER

CIBER NUEVO LOGO

Contact information

Centro de Investigación Médica en Red (CIBER)
Luzma García Piqueres, responsable de Transferencia de TecnologíaHead of Technology Transfer
C/ Monforte de Lemos 3-5. Pabellón 11
Madrid
Madrid
(+34) 911718122
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biomarkers
      • Stem cells
      • Cell cultures
      • In vitro diagnostics
      • Medical devices
      • Drug delivery
      • Drug development
      • Screening
      • Cellular Therapy
      • Gene Therapy
      • Biomaterials and tissue therapy
      • Transplant
      • Vaccines
    • Therapeutic areas
      • Cardiovascular diseases and circulatory system
      • Genetic and rare diseases
      • Inflammatory diseases
      • Oncology
      • Digestive system and hepatology
      • Respiratory and pulmonary system
      • Metabolic disorders / Endocrinology
  • D. Services
    • Professional services
      • Supplies and materials providers

The aim of the Consorcio Centro de Investigación Biomédica en Red, M.P, CIBER, a public research consortium set up at the initiative of the Instituto de Salud Carlos III (ISCIII), is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System.

To this end efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.

Products and services

One of the main missions of the CIBER is the translation of knowledge, so that the results of research that we generate are developed in protocols, services and products for the improvement of clinical practice and people’s quality of life.

The technology transfer unit thus wishes to offer our researchers and companies, other private institutions and public research centres the capacities of our groups and technologies that they develop by:

  • Licensing and co-development of our technologies.

  • Undertaking clinical assays.

  • Participation in one of our spin offs.

  • Other forms of cooperation.

 

Biotech Sanitaria

Diagnostics and Personalised Medicine
Product / Service Type Therapeutic area Development phase
SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments Enfermedades infecciosas, Sistema respiratorio y pulmonar Preclinical
Methods for the measurement of protein C and activated protein C Biomarkers, Diagnostic Inmunología, Enfermedades infecciosas Preclinical
USE OF AN MNK kinase inhibitor for the treatment of Triple-negative breast cancer Biomarkers, Diagnostic Oncología R&D
SALIVA-BASED DIAGNOSTIC TEST FOR EOSINOPHILIC OESOPHAGITIS Biomarkers Sistema digestivo y hepatología R&D
SEPARATION-OF-FUNCTION I KAPPA B ALPHA MUTANTS Biomarkers, Diagnostic Oncología Preclinical
PREDICTION OF ACUTE RESPIRATORY DISTRESS IN COVID-19 PATIENTS Diagnostic Sistema respiratorio y pulmonar Preclinical
PredictivModel to predict the development of type 2 diabetes mellitus using miRNAs Biomarkers, Diagnostic Trastornos metabólicos / Endocrinología R&D
New predictive method for the progression of colorectal cancer Biomarkers Oncología Preclinical
NON-INVASIVE METHOD FOR COLORECTAL CANCER DETECTION Biomarkers Oncología R&D
METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS Diagnostic Sistema respiratorio y pulmonar Preclinical
Method for rapid detection of Candida auris and diagnosis of infection caused by this pathogen Diagnostic Enfermedades infecciosas Preclinical
METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE Diagnostic Sistema respiratorio y pulmonar Preclinical
METHOD FOR MONITORING OR PREDICTING WHETHER A PATIENT SUFFERING FROM OBESITY IS RESPONDING OR WILL RESPOND TO A VERY-LOW-CALORIE KETOGENIC DIET (VLCKD) Biomarkers, Diagnostic Trastornos metabólicos / Endocrinología Preclinical
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques Biomarkers, Diagnostic Sistema nervioso central R&D
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques Diagnostic Sistema nervioso central Preclinical
IDENTIFICATION OF METABOLOMIC SIGNATURES IN URINE SAMPLES FOR TUBERCULOSIS DIAGNOSIS Biomarkers, Diagnostic Enfermedades infecciosas Preclinical
INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION Biomarkers, Diagnostic Sangre y sistema linfático R&D
Epigenetic biomarkers for the diagnosis and prevention of the evolution of obesity Biomarkers, Diagnostic Trastornos metabólicos / Endocrinología R&D
Haptens, antibodies and method to detect pseudomonas aeruginosa infections Diagnostic Enfermedades infecciosas R&D
ceRNA profile to predict response to immunotherapy in cancer patients Diagnostic Oncología Preclinical
CIRCULATING miRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER´S DISEASE Biomarkers, Diagnostic Sistema nervioso central R&D
BIOMARKERS TO PREDICT LUNG OVERSTRETCHING Biomarkers, Diagnostic Sistema respiratorio y pulmonar Clinical Validation
BIOSIGNATURES FOR ULCERATIVE COLITIS Biomarkers Sistema digestivo y hepatología R&D
BIOMARKERS AND DIAGNOSTIC METHOD FOR MODY NHF1A Biomarkers, Diagnostic Trastornos metabólicos / Endocrinología R&D
Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up Biomarkers, Diagnostic Oncología R&D